News

Under-the-skin Velcade Found to Work Better in Farydak Triple Combo

Using an under-the-skin formulation of Velcade (bortezomib), in combination with Farydak (panobinostat) and oral dexamethasone, leads to a better safety profile in people with relapsed or refractory (resistant) multiple myeloma than does the therapy’s original into-the-vein version, data show. The triple combination treatment with under-the-skin Velcade also was…

EMA Plans Speedy Review of Cilta-cel, CAR T-cell Therapy for Advanced Myeloma

An accelerated review will be given an application for European Union approval of ciltacabtagene autoleucel (cilta-cel), a potential CAR T-cell therapy for heavily pre-treated multiple myeloma patients, its developer, Janssen, announced. An accelerated assessment, given to medications expected to have a major impact on public health, shortens the regulatory review process…

EU Committee Supports Nexpovio for Heavily Treated Myeloma Patients

A combination of Nexpovio (selinexor) and the corticosteroid dexamethasone has been recommended for conditional approval in the European Union to treat adults with relapsed or refractory multiple myeloma who received at least four prior therapies. This includes patients whose disease failed to respond to at least two proteasome inhibitors,…

Dosing Begins in Phase 1 Trial of CERC-007

Cerecor has dosed the first patient in a Phase 1b clinical trial evaluating  CERC-007 as a potential treatment for relapsed or refractory multiple myeloma. The trial (NCT04671251) intends to enroll up to 30 adult patients who received prior treatment with a proteasome inhibitor, an immunomodulatory agent, and…

Jakafi Plus Steroid Continuing to Treat Multiple Myeloma in Phase 1 Trial

Combining the corticosteroid methylprednisolone and Jakafi (ruxolitinib), an approved oral therapy for bone marrow disorders, is showing promising effectiveness in heavily pre-treated multiple myeloma patients in an ongoing Phase 1 trial. Findings to date from this open-label study (NCT03110822), which is being sponsored by Onco Therapeutics, showed…

$10M Gift to Open Myeloma Research Center at Ohio State

A new research center at Ohio State University (OSU) aims to speed work into the discovery and development of more effective treatments for those with multiple myeloma. The Riney Family Foundation Myeloma Center for Advanced Research Excellence (Myeloma CARE) is being established through a $10 million gift from the…

First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy

The first patient has been dosed in Celyad Oncology’s Phase 1 clinical trial evaluating CYAD-211, an investigational donor-derived CAR T-cell therapy for treating relapsed or refractory multiple myeloma. The IMMUNICY-1 trial (NCT04613557) intends to recruit 12 patients who received two or more prior lines of treatment, including…

FDA Gives Orphan Drug Status to Potential Multiple Myeloma Immunotherapy

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Harpoon Therapeutics‘ investigational immunotherapy HPN217 as a possible treatment of multiple myeloma. The designation encourages the development of potential therapies for rare and serious diseases by granting them various financial and regulatory benefits. These include exemptions from…